• Reference Citation Analysis
  • v
  • v
  • Find an Article
Find an Article PDF (4591707)   Today's Articles (1619)   Subscriber (49315)
Number Citation Analysis
1
Comment on “Estimands for Recurrent Event Endpoints in the Presence of a Terminal Event”. Stat Biopharm Res 2022. [DOI: 10.1080/19466315.2022.2029556] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
2
Statement on P-values. Stat Biopharm Res 2021. [DOI: 10.1080/19466315.2021.1886164] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
3
Commentary on “Applying CHW method to 2-in-1 design: gain or lose”. J Biopharm Stat 2019;29:722-727. [DOI: 10.1080/10543406.2019.1634088] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
4
Statistical inference problems in sequential parallel comparison design. J Biopharm Stat 2019;29:1116-1129. [DOI: 10.1080/10543406.2019.1609014] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
5
Rejoinder to “Statistical inference problems in sequential parallel comparison designs”. J Biopharm Stat 2019;29:1134-1136. [DOI: 10.1080/10543406.2019.1609017] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
6
2017 Cardiovascular and Stroke Endpoint Definitions for Clinical Trials. J Am Coll Cardiol 2018;71:1021-1034. [DOI: 10.1016/j.jacc.2017.12.048] [Citation(s) in RCA: 148] [Impact Index Per Article: 24.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/23/2017] [Revised: 12/21/2017] [Accepted: 12/22/2017] [Indexed: 11/25/2022]
7
2017 Cardiovascular and Stroke Endpoint Definitions for Clinical Trials. Circulation 2018;137:961-972. [DOI: 10.1161/circulationaha.117.033502] [Citation(s) in RCA: 214] [Impact Index Per Article: 35.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/23/2017] [Accepted: 12/22/2017] [Indexed: 11/16/2022]
8
Adaptive enrichment with subpopulation selection at interim: Methodologies, applications and design considerations. Contemp Clin Trials 2013;36:673-81. [DOI: 10.1016/j.cct.2013.09.008] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/21/2013] [Revised: 09/13/2013] [Accepted: 09/16/2013] [Indexed: 10/26/2022]
9
Genomic Classifier for Patient Enrichment: Misclassification and Type I Error Issues in Pharmacogenomics Noninferiority Trial. Stat Biopharm Res 2011. [DOI: 10.1198/sbr.2010.10012] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
10
Comment on “PISC Expert Team White Paper: Toward a Consistent Standard of Evidence When Evaluating the Efficacy of an Experimental Treatment From a Randomized Active-Controlled Trial”. Stat Biopharm Res 2010. [DOI: 10.1198/sbr.2010.09016comm1] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
11
Considerations in Adapting Clinical Trial Design. J Formos Med Assoc 2008;107:14-8. [DOI: 10.1016/s0929-6646(09)60004-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]  Open
12
On some statistical methods for analysis of combination drug studies∗. COMMUN STAT-THEOR M 2007. [DOI: 10.1080/03610929408831260] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
13
Utilities of theP-value Distribution Associated with Effect Size in Clinical Trials. Biom J 2003. [DOI: 10.1002/bimj.200390040] [Citation(s) in RCA: 17] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
14
Estimation and Confidence Intervals after Adjusting the Maximum Information. Biom J 2003. [DOI: 10.1002/bimj.200390001] [Citation(s) in RCA: 40] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
PrevPage 1 of 1 1Next
© 2004-2024 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA